When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
IMV - Mid-stage study of IMV's DPX-Survivac in ovarian cancer underway
IMV Inc.
Enrollment is underway in an 85-subject Phase 2 clinical trial, DECIDE, evaluating IMV's (IMV) T cell-activating immunotherapy DPX-Survivac plus chemo agent cyclophosphamide in patients with advanced platinum-sensitive and platinum-resistant ovarian cancer.